Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects

• Published in: Clinical drug investigation Vol. 42; no. 11; pp. 1009 - 1016
• Main Authors: Meng, Xianmin, Lin, Xiaoyan, Jiang, Rongrong, Lu, Yan, Zeng, Liyan, Cao, Ming, Zhang, Jianliang
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2022; Springer Nature B.V
• Subjects: Adenosine diphosphate; Administration, Oral; Apoptosis; Area Under Curve; Bioavailability; Biological Availability; China; Clinical medicine; Cross-Over Studies; DNA damage; Drug dosages; Food; Food-Drug Interactions; Health care; Healthy Volunteers; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; NCT; NCT04057729; Oral administration; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Public health; China
• ISSN: 1173-2563; 1179-1918; 1179-1918
• DOI: 10.1007/s40261-022-01198-8

Background and Objectives Data on the effect of food on the pharmacokinetics of senaparib (previously IMP4297), an oral poly (adenosine diphosphate-ribose) polymerase inhibitor, are limited. This study was conducted to evaluate the effect of food on the pharmacokinetics of senaparib in healthy Chinese subjects. Methods This is a phase I, open-label, randomized, single-dose, two-way crossover study. Healthy Chinese male subjects were randomized 1:1 to receive a single dose of senaparib 100 mg in two prandial states: fasted or after a high-fat meal; subjects were given a second dose after switching prandial states and a washout period of at least 7 days. Pharmacokinetics were assessed at pre-dose and up to 72 h post-dose. Safety was assessed throughout the study. Results Sixteen subjects were randomized and included in the pharmacokinetic analysis; 15 completed the study. The presence of food slowed the rate of senaparib absorption (time to maximum concentration) by ~ 3 h and reduced the maximum concentration of senaparib by ~ 24%. Total exposure to senaparib was higher in the fed than fasted state; senaparib area under the plasma concentration–time curve from time zero to the last measurable concentration and area under the plasma concentration–time curve from time zero to infinity were increased by ~ 24 and ~28%, respectively. Safety profiles were similar in both prandial states. All treatment-emergent adverse events were grade 1 in severity; no serious adverse events or deaths were reported. Conclusions Food slightly decreased the rate and increased the extent of senaparib absorption following oral administration. However, the effect of food on various exposure parameters was not considered clinically meaningful. Safety data were consistent with the known profile of senaparib and senaparib was well tolerated in the fed and fasted states in healthy subjects. These results indicated that senaparib could be administered orally with or without food. Clinical Trial Registration ClinicalTrials.gov NCT04057729.